GlassScriptPhysician profile
Paul G Termini
NPI 1427125764
$11,749.79
in general payments reported to CMS, 2019-2025
29 companies · $1,546 in 2025
The $1,546 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.73 · 2021: $2,574 · 2022: $2,326 · 2023: $2,402 · 2024: $2,855 · 2025: $1,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,802.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,145.76 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,106.20 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,072.24 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $953.62 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $859.89 | 2021-2025 | Ingrezza |
| Abbvie INC. | $741.66 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $656.44 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $623.69 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Bausch Health US, LLC | $623.08 | 2020-2025 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $504.77 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $353.43 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $352.32 | 2021-2024 | Fanapt, Hetlioz |
| Eisai INC. | $329.14 | 2021-2024 | |
| Corium, LLC | $323.45 | 2022-2024 | Azstarys |
| Jazz Pharmaceuticals INC. | $307.78 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $263.58 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $259.11 | 2021-2024 | Qelbree, Qelbree |
| Alfasigma USA, INC. | $229.46 | 2021 | |
| Neos Therapeutics, LP | $228.70 | 2021-2024 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $216.43 | 2022-2025 | Loreev Xr |
| Novo Nordisk INC | $202.19 | 2023-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $108.14 | 2021-2023 | Belsomra |
| Indivior INC. | $100.38 | 2020-2022 | |
| Noven Therapeutics, LLC | $40.80 | 2022 | |
| Avanir Pharmaceuticals, INC. | $40.53 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $39.89 | 2021 | |
| Idorsia Pharmaceuticals US INC | $31.38 | 2023 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $19.71 | 2024 | Lumryz |
| Acadia Pharmaceuticals INC | $16.02 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Termini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.